Nurix Therapeutics (NRIX) EBIT Margin (2019 - 2025)
Historic EBIT Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 612.03%.
- Nurix Therapeutics' EBIT Margin fell 1253000.0% to 612.03% in Q4 2025 from the same period last year, while for Nov 2025 it was 340.16%, marking a year-over-year increase of 503600.0%. This contributed to the annual value of 340.16% for FY2025, which is 503600.0% up from last year.
- Per Nurix Therapeutics' latest filing, its EBIT Margin stood at 612.03% for Q4 2025, which was down 1253000.0% from 1157.65% recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' EBIT Margin ranged from a high of 87.25% in Q2 2023 and a low of 1157.65% during Q3 2025
- Its 5-year average for EBIT Margin is 420.45%, with a median of 400.65% in 2022.
- Per our database at Business Quant, Nurix Therapeutics' EBIT Margin skyrocketed by 4187700bps in 2023 and then crashed by -7238200bps in 2025.
- Nurix Therapeutics' EBIT Margin (Quarter) stood at 513.16% in 2021, then plummeted by -40bps to 717.82% in 2022, then skyrocketed by 58bps to 299.06% in 2023, then crashed by -63bps to 486.73% in 2024, then decreased by -26bps to 612.03% in 2025.
- Its last three reported values are 612.03% in Q4 2025, 1157.65% for Q3 2025, and 109.68% during Q2 2025.